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POLICY BRIEF
Medical Innovation and the
Employment of Cancer Patients
R. Vincent Pohl
BRIEF HIGHLIGHTS
n Innovations in cancer treatment
may alleviate the economic costs of
cancer diagnoses, such as a decline of
labor supply.
n I measure innovation during the
1990s and 2000s by the number of
approved drugs and patents related to
cancer diagnosis and treatment.
n Using cancer registry and tax
return data from Canada, we
investigate the employment outcomes
of breast and prostate cancer patients
as a function of medical innovation.
n Medical innovation reduces the
negative employment effect of cancer
diagnoses by about 65 percent during
the study period.
n The economic benefits of
medical innovation are limited to
cancer patients with postsecondary
education, raising concerns about
equal access to new treatments.

C
ancer is the second-most common cause of mortality and morbidity in developed
countries. In addition to its direct costs in terms of quality-adjusted life years lost, it also

contributes to the economic costs of disease as cancer patients often reduce their working
hours or cease employment completely.
Recent decades have seen increased innovation in the treatment of many types of
cancer. Pharmaceutical innovation has resulted in new chemotherapy drugs—often used
in combinations—that are more effective in targeting tumors while reducing harm for
healthy body tissue. In addition, new surgical techniques alleviate side effects and lead to
shorter recovery times.
I investigate whether medical innovation in the treatment of breast and prostate
cancers, which are the most common types of cancers among women and men,
respectively, also lead to a reduction in the economic costs of cancer. Specifically, I use
large administrative databases from Canada to estimate how the employment effect
of a cancer diagnosis is moderated by medical innovation. I employ a difference-indifferences strategy combined with matching to estimate the causal effect of a cancer
diagnosis and how it changes with medical innovation.
Confirming previous research, I first find that a cancer diagnosis reduces employment
by 2 to 4 percentage points. Second, the cumulative medical innovation that improved
cancer treatment during the 1990s and 2000s led to a decrease in the negative
employment effects of prostate and breast cancer by about 65 percent. Hence, the
approval of additional drugs and the introduction of other medical technologies over this
time period are associated with a substantial reduction in the economic costs of cancer.
Finally, I consider the employment effects of cancer diagnoses and medical innovation by
cancer patients’ education. I find that the benefits of innovation are limited to individuals
with postsecondary education, although cancer patients with lower levels of education
experience a larger decline in employment.
The results suggest that innovations in cancer treatment may provide benefits beyond
direct medical effects. As innovative cancer treatments can be very expensive, it is
therefore important to account for economic benefits such as smaller reductions in labor
income and, as a result, tax revenue when determining whether the benefits of a new
treatment option outweigh its cost. The heterogenous effects by education indicate that
the mere existence of new medical technology may not automatically lead to improved
economic outcomes, but rather that there are barriers to access them.

Background
For additional details, see the full working
paper at https://research.upjohn.org/up_
workingpapers/306/.

The most common types of cancers are breast and prostate, affecting about 26,000
women and 21,000 men, respectively, in Canada annually. While most cancers affect
older individuals, a substantial subgroup of breast and prostate cancer patients is
diagnosed during their working age. Because cancer treatment is lengthy and can cause
severe side effects, patients undergoing treatment often reduce their labor supply or stop
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The annual average
earnings losses due to a
prostate and breast cancer
diagnosis are $1,100 and
$600 lower, respectively,
than they would have
been without medical
innovation.

working completely. These negative labor market effects may be alleviated by improved
treatment options that are more likely to cure cancer in a shorter amount of time and
lead to fewer side effects.
To investigate the effect of cancer diagnoses and medical innovation on employment,
I combine data from several sources. First, I identify breast and prostate cancer patients
from the Canadian Cancer Database. Second, I use individual tax returns from the
Longitudinal Worker File to measure employment of cancer patients before and after
their diagnosis, as well as employment of individuals who were never diagnosed with
cancer and who serve as a control group. Statistics Canada merged these data sets to the
1991 population census, which contains individual characteristics such as education.
Finally, I measure medical innovation in two different ways. A first, more narrow
measure is the number of drugs that are approved for the treatment of breast and prostate
cancer. Pharmaceutical innovation is important, as chemotherapy is one of the main
treatment options for cancer. Throughout the study period, the 1990s and 2000s, several
important new drugs were approved, including the chemotherapy drug trastuzumab for
the treatment of breast cancer, and triptorelin, a luteinizing hormone-releasing hormone
analogue used to fight prostate cancer.
In addition to chemotherapy, surgery and radiation are used as cancer treatment.
Notable innovations include laparoscopic radical prostatectomy, a minimally invasive
surgical technique, and breast-conserving surgery, both of which reduce recovery time
and potential side effects after surgery. To broadly capture innovation in these areas, I use
international patent data. From these records, I construct a quality-weighted patent index
that measures the aggregate and cumulative innovative activity related to breast and
prostate cancer treatment.
Before I estimate the effect of cancer diagnoses and medical innovation on
employment, I use a matching technique to create a control group consisting of
individuals without cancer that is identical to cancer patients along all observed
dimensions. I then employ a difference-in-differences strategy—I compare employment
rates of cancer patients and the matched control group both before and after the cancer
diagnosis. I consider a five-year window before and after the diagnosis and allow the
employment effects of cancer diagnoses and medical innovation to vary over time, as it is
plausible that these effects do not remain constant within this time frame.

Results
I find that some breast and prostate cancer patients reduce their employment after the
diagnosis when compared to the matched control group. Men are 1.8 percentage points
less likely to be employed after a prostate cancer diagnosis, and women are 3.9 percentage
points less likely to be employed after a breast cancer diagnosis.
Medical innovation substantially reduces the negative employment effects of cancer
diagnoses. Figure 1 shows the effect of a prostate cancer diagnosis on employment as
a function of the number of drugs available for the treatment of this disease. In 1992
when 14 drugs were approved, employment of prostate cancer patients drops by a
few percentage points initially, and the decline reaches more than 5 percentage points
after three years (solid blue line; I show the effects prior to the diagnosis to rule out
any preexisting trends). In contrast, when 27 approved drugs were available in 2010, a
prostate diagnosis reduces employment by only about 1 percentage point during the first
five years (dashed red line).
For the employment effects of breast cancer diagnoses and the role of medical
innovation, Figure 2 shows a similar pattern. As the number of drugs approved for the
treatment of breast cancer increased from 17 to 39 between 1992 and 2010, the decline in
employment following a diagnosis became smaller. At the lowest level of pharmaceutical
innovation, breast cancer reduces employment by about 2.5 percentage points initially
and up to 5 percentage points three years after the diagnosis and beyond (solid blue line).
At the highest number of drugs available, the initial decline in employment is similar, but
2
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The fact that only highly
educated individuals
profit from innovative
cancer treatments
suggests that the
economic benefits of
medical innovation are
distributed unequally.
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Figure 1 Effect of Prostate Cancer on Employment by Number of Approved Drugs
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SOURCE: Statistics Canada and author’s calculations.

after three years, the employment effect becomes indistinguishable from 0 (dashed red
line).
When repeating this exercise with the quality-weighted patent index instead of
the number of approved drugs, I find similar patterns (not shown). Hence, I provide
evidence suggesting that medical innovation in the form of new drugs and medical
technology alleviates the economic costs of breast and prostate cancer diagnoses. On
average, medical innovation reduces the decline in employment among cancer patients
by about 65 percent between 1992 and 2010. These effects imply that the annual average
earnings losses due to a prostate and breast cancer diagnosis are $1,100 and $600 lower,
respectively, than they would have been without medical innovation. Therefore, a
Figure 2 Effect of Breast Cancer on Employment by Number of Approved Drugs
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Encouraging and
subsidizing medical
innovation may have the
dual benefit of mitigating
both the medical and
economic consequences of
cancer and other diseases.

substantial economic benefit arises from these innovations, in addition to any resulting
reductions in mortality and morbidity.
To better understand how education interacts with medical innovation in the
employment of cancer patients, I split the sample by education into individuals without
a high school degree, those who have graduated from high school but have no further
education, and those with at least some postsecondary education. Among these
subsamples, I only observe a mitigating impact of medical innovation on the negative
employment effect of cancer diagnoses for breast and prostate cancer patients with
postsecondary education. In contrast, individuals with lower levels of education reduce
their employment by more than those with postsecondary education.
Although the data do not allow me to determine the underlying mechanism, there
are several potential explanations for the observed heterogeneity by education. First,
higher levels of education may help cancer patients identify medical providers who
use innovative treatments. Second, education may enable cancer patients to obtain
information on treatment options and demand that their medical providers use up-todate treatments. Third, adherence to complex treatment regimens could be facilitated
by higher educational attainment. Finally, it is possible that cancer patients with low
education levels work in physically more demanding jobs where it is more difficult
to undergo a modern high-intensity cancer treatment while remaining employed.
Independent of the actual mechanism, the fact that only highly educated individuals
profit from innovative cancer treatments suggests that the economic benefits of medical
innovation are distributed unequally.

Implications
The empirical findings have several important implications. First, they highlight the
importance of accounting for indirect (economic) benefits in a cost-benefit analysis of
new medical technologies. Although the benefits in terms of lower earnings losses are
smaller by an order of magnitude than the annual cost of an intensive cancer treatment,
which can exceed $100,000, the benefits are substantial. Therefore, they should be
considered in addition to potential improvements in terms of mortality and morbidity.
Second, the findings suggest potential policies that can alleviate the economic costs
of disease. It is of particular concern that cancer patients experience lower employment
rates and hence earnings losses in addition to the pain and suffering caused by their
disease. Thus, encouraging and subsidizing medical innovation may have the dual benefit
of mitigating both the medical and economic consequences of cancer and other diseases.
Investments in research that lead to new treatment options may very well have a positive
return if the resulting innovation has economic in addition to medical benefits.
Last, the fact that medical innovation does not yield economic gains for cancer
patients with lower levels of education raises concerns about unequal access to upto-date treatment options. Especially when medical research is publicly financed, it is
reasonable to expect that resulting innovation should benefit cancer patients irrespective
of their demographic or socioeconomic background. Moreover, in the case of the
employment effects of cancer diagnoses, individuals with the lowest levels of education
suffer the highest economic cost. Therefore, policymakers may need to ensure that new
and innovative treatment options are accessible to all patients who would benefit from
them, such as through information campaigns targeted at these individuals. In addition,
medical education could increasingly emphasize the importance of accounting for
patients’ socioeconomic backgrounds in choosing appropriate cancer treatments.
In sum, these findings highlight the importance of considering interactions between
labor markets and health care and point out several policy options aimed at reducing the
economic burden of disease.
W.E. Upjohn Institute for
Employment Research
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